However, there was no evidence that kinase inhibitor treated EGFR-mutated NSCLC and HCC individual harbored BIM deletion polymorphism improved OS in comparison with those with BIM wild polymorphism. The gene discussed is EGFR; the disease is hepatocellular carcinoma.